Schering-Plough

Orwin joins Array BioPharma’s board of directors

Friday, November 9, 2012 02:29 PM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs for the treatment of cancer, has appointed John A. Orwin, CEO of Affymax, to Array's board of directors as part of its continued evolution toward late-stage development and commercialization.

More... »

Delcath appoints Chris Houchins senior VP

Tuesday, February 14, 2012 07:50 AM

Delcath Systems has appointed J. Chris Houchins to the company's clinical development team as senior vice president, clinical and medical affairs.

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Merck restructures with job cuts

Tuesday, September 20, 2011 10:23 AM

A few weeks ago, Merck disclosed plans to trim another 12,000 to 13,000 jobs by the end of 2015 in order to save up to $1.5 billion. This is on top of previously announced cuts although efforts to reduce headcount are forcing managers to accelerate their plans, according to Pharmalot.

More... »

Regeneron names LaRosa senior VP

Tuesday, September 6, 2011 12:44 PM

Regeneron Pharmaceuticals has named Joseph J. LaRosa senior vice president, general counsel and secretary. LaRosa will be responsible for overseeing all legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.

More... »

Merck receives subpoena regarding marketing and selling of drugs

Monday, August 8, 2011 01:34 PM

Merck has received a subpoena from the US Department of Justice as part of a criminal investigation into the marketing of various drugs. The feds want info about marketing and selling these drugs - Temodar, which treats brain tumors; the PegIntron hepatitis C treatment; and Intron A, which treats certain cancers - from 2004 through the present, according to Pharmalot.

More... »

Merck to cut 12K jobs

Friday, July 29, 2011 12:55 PM

Merck plans to slash thousands more jobs by late 2015 to wring out additional annual cost savings of up to $1.5 billion that can be plowed back into research and deal making, according to Reuters.

More... »

Merck continues plans to cut jobs

Friday, July 15, 2011 10:07 AM

Last year, Merck disclosed plans to save up to $3.5 billion by closing numerous research sites and manufacturing plants and eliminate roughly 15,000 jobs by 2012, or roughly 10% of the total headcount including the thousands of employees who were part of the 2009 acquisition of Schering-Plough. Before that deal, Merck employed about 53,000 people, reported Pharmalot.

More... »

Merck strategically shedding compounds

Thursday, July 7, 2011 10:05 AM

Almost as soon as the Merck and Schering-Plough pipelines were combined in late 2009, Merck had to go through all of its compounds and decide which to shed, according to Chemical & Engineering News.

More... »

Actelion board nominates two

Wednesday, April 6, 2011 12:40 PM

Actelion has nominated two pharmaceutical executives, including ex-GlaxoSmithKline boss Jean-Pierre Garnier, to join the board after shareholder Elliott Advisors repeated calls for changes in management and strategy, according to Pharma Times.

More... »